Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses

Oncogene

Volumn 24, Issue 52, 2005, Pages 7792-7801

  Working, Peter K ^a   Lin, Andy ^a   Borellini, Flavia ^a  

^a CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CANCER VACCINE; CG 0070; CG 7060; CG 7870; CV 716; CYTOKINE; ENZYME; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OAS 403; ONCOLYTIC ADENOVIRUS VACCINE; ONCOLYTIC VIRUS; ONYX 411; UNCLASSIFIED DRUG; VIRUS VACCINE; WI 38;

ADENOVIRUS; BIOENGINEERING; BIOTECHNOLOGY; DRUG EFFECT; DRUG MANUFACTURE; DRUG POTENCY; DRUG PURITY; DRUG SAFETY; DRUG STABILITY; GENETIC RECOMBINATION; GENETIC STABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRAL GENETICS; VIRUS MUTATION; WILD TYPE;

ADENOVIRIDAE; BIOTECHNOLOGY; GENETIC ENGINEERING; GUIDELINES; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; QUALITY CONTROL; SAFETY;

ADENOVIRIDAE; ONYX;

EID: 27944472282     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209045     Document Type: Review

References (35)

1. Alemany RC and Curiel DT. (2001). Gene Therapy, 8, 1347-1353.
2. Alemany RC, Lai S, Lou YC, Jan HY, Fang X and Zhang WW. (1999). Cancer Gene Ther., 6, 21-25.
3. Bernt RM, Liang M, Ye X, Ni S, Li ZY, Ye SL, Hu F and Lieber A. (2002). J. Virol., 76, 10994-11002.
4. Biederer C, Reis S, Brandts CH and McCormick F. (2002). J. Mol. Med., 80, 163-175.
5. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F. (1996). Science, 274, 373-376.
6. Bristol JA, Zhu M, Ji H, Mina M, Xie Y, Clarke L, Forry-Schaudies S and Ennist DL. (2003). Mol. Ther., 7, 755-764.
7. Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, Krasnykh and Curiel DT. (1999). Nat. Biotechnol., 17, 470-475.
8. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D and Hoeben RC. (1998). Hum. Gene Ther., 9, 1909-1917.
9. Farson D, Tao L, Ko D, Harding T, Li Q, Brignetti D, Yu DC and Li Y. (2005). Proceedings of American Society of Gene Therapy Annual Meeting. St Louis, MO, USA.
10. Farson D, Tao L, Ko D, Harding T, Yu DC and Li Y. (2004). Proceedings of American Society of Gene Therapy Annual Meeting. Minneapolis, MN, USA.
11. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD and Kim JH. (1998). Hum. Gene Ther., 9, 1323-1333.
12. Graham FL, Smiley J, Russell WC and Nairn R. (1977). J. Gen. Virol., 36, 59-74.
13. Haviv YS and Curiel DT. (2003). Curr. Gene Ther., 3, 357-385.
14. Hehir KM, Armentano D, Cardoza LM, Choquette TL, Berthelette PB, White GA, Couture LA, Everton MB, Keegan J, Martin JM, Pratt DA, Smith MP, Smith AE and Wadsworth S. (1996). J. Virol., 70, 8459-8467.
15. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L and Kirn D. (2000). Nat. Med., 6, 1134-1139.
16. Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R and Curiel DT. (2001). Cancer Res., 61, 6377-6381.
17. Henderson D, Chen Y and Yu D. (2001). Replication-Competent Viruses for Cancer Therapy. Hernaiz Driever P and Rabkin SD (eds). Karger: Basel, pp. 56-80.
18. Henderson D and Yu D. (2002). Adenoviral Vectors for Gene Therapy. Curiel D and Douglas J (eds). Academic Press: San Diego, pp. 287-319.
19. Johnson L. (2002). Cancer Cell, 1, 325-337.
20. Jones SD and Levine HL. (2004). Preclinica, 2, 301-304.
21. Kirn D. (2001). Gene Therapy, 8, 89-98.
22. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao YF, Miyazono K, Urabe A and Takaku F. (1989). J. Cell Physiol., 140, 323-334.
23. Lusky M. (2005). Hum. Gene Ther., 16, 281-291.
24. Murakami P, Havenga M, Fawaz F, Vogels R, Marzio G, Pungor E, Files J, Do L, Goudsmit J and McCaman M. (2004). J. Virol., 78, 6200-6208.
25. Murakami P, Pungor E, Files J, Do L, Van Rijnsoever R, Vogels R, Bout A and McCaman M. (2002). Hum. Gene Ther., 13, 909-920.
26. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D and McCormick F. (2004). Cancer Cell, 6, 611-623.
27. Reid T, Warren R and Kirn D. (2002). Cancer Gene Ther., 9, 979-986.
28. Ryan PC, Jakubczak JL, Stewart DA, Hawkins LK, Cheng C, Clarke LM, Ganesh S, Hay C, Huang Y, Kaloss M, Marinov A, Phipps SS, Reddy PS, Shirley PS, Skripchenko Y, Xu L, Yang J, Forry-Schaudies S and Hallenbeck PL. (2004). Cancer Gene Ther., 11, 555-569.
29. Shen Y. (2003). Twelfth International Conference on Gene Therapy of Cancer. San Diego, CA, USA.
30. Smith JG and Eck SL. (1999). Cancer Gene Ther., 6, 475-481.
31. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT and Alemany R. (2001). Clin. Cancer Res., 7, 120-126.
32. Wakimoto H, Johnson PR, Knipe DM and Chiocca EA. (2003). Gene Therapy, 10, 983-990.
33. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, Nguyen N, Amin P, Oh J and Henderson DR. (2001). Cancer Res., 61, 517-525.
34. Yu DC, Chen Y, Seng M, Dilley J and Henderson DR. (1999). Cancer Res., 59, 4200-4203.
35. Yu DC, Working PK and Ando D. (2002). Curr. Opin. Mol. Ther., 4, 435-443.